Literature DB >> 11420671

Sustained activation of the Raf/MEK/Erk pathway in response to EGF in stable cell lines expressing the Hepatitis C Virus (HCV) core protein.

S Giambartolomei1, F Covone, M Levrero, C Balsano.   

Abstract

Chronic hepatitis C virus (HCV) infection is a leading cause of liver cirrhosis and hepatocellular carcinoma (HCC) worldwide. The HCV capside core is a multifunctional protein with regulatory functions that affects transcription and cell growth in vitro and in vivo. Here, we show that both HCV genotype 1a and 3 core proteins activate MEK1 and Erk1/2 MAP kinases and that the costitutive expression of the HCV core results in a high basal activity of Raf1 and MAP/kinase/kinase, as determined by endogenous Raf1 in vitro kinase assay and immunodetection of hyperphosphorylated Erk1 and Erk2 even after a serum starvation. Moreover, the activation of both Erk1/2 and the downstream transcription factor Elk-1 in response to the mitogenic stimulus EGF is significantly prolonged. The sustained response to EGF in cells expressing the HCV core occurs despite a normal induction of the MAP phosphatases MKP regulatory feedback and is likely due to the costitutive activation of Raf-1 activity. The ability of HCV core proteins to directly activate the MAP kinase cascade and to prolong its activity in response to mitogenic stimuli may contribute to the neoplastic transformation of HCV infected liver cells.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11420671     DOI: 10.1038/sj.onc.1204372

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  48 in total

1.  Hepatocyte transformation and tumor development induced by hepatitis C virus NS3 c-terminal deleted protein.

Authors:  Qiong-Qiong He; Rui-Xue Cheng; Yi Sun; De-Yun Feng; Zhu-Chu Chen; Hui Zheng
Journal:  World J Gastroenterol       Date:  2003-03       Impact factor: 5.742

2.  The vaccinia virus-stimulated mitogen-activated protein kinase (MAPK) pathway is required for virus multiplication.

Authors:  Anderson A Andrade; Patrícia N G Silva; Anna C T C Pereira; Lirlândia P De Sousa; Paulo C P Ferreira; Ricardo T Gazzinelli; Erna G Kroon; Catherine Ropert; Cláudio A Bonjardim
Journal:  Biochem J       Date:  2004-07-15       Impact factor: 3.857

3.  The hepatitis E virus open reading frame 3 protein activates ERK through binding and inhibition of the MAPK phosphatase.

Authors:  Anindita Kar-Roy; Hasan Korkaya; Ruchi Oberoi; Sunil Kumar Lal; Shahid Jameel
Journal:  J Biol Chem       Date:  2004-04-19       Impact factor: 5.157

4.  Endocytosis of hepatitis C virus non-enveloped capsid-like particles induces MAPK-ERK1/2 signaling events.

Authors:  Konstantina Katsarou; Alexandros Alpha Lavdas; Panagiota Tsitoura; Elisavet Serti; Panagiotis Markoulatos; Penelope Mavromara; Urania Georgopoulou
Journal:  Cell Mol Life Sci       Date:  2010-04-01       Impact factor: 9.261

5.  Phase 2 study of bevacizumab plus erlotinib in patients with advanced hepatocellular cancer.

Authors:  Philip A Philip; Michelle R Mahoney; Kyle D Holen; Donald W Northfelt; Henry C Pitot; Joel Picus; Patrick J Flynn; Charles Erlichman
Journal:  Cancer       Date:  2011-09-27       Impact factor: 6.860

Review 6.  Novel insights into the function and dynamics of extracellular matrix in liver fibrosis.

Authors:  Morten A Karsdal; Tina Manon-Jensen; Federica Genovese; Jacob H Kristensen; Mette J Nielsen; Jannie Marie B Sand; Niels-Ulrik B Hansen; Anne-Christine Bay-Jensen; Cecilie L Bager; Aleksander Krag; Andy Blanchard; Henrik Krarup; Diana J Leeming; Detlef Schuppan
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2015-03-12       Impact factor: 4.052

7.  Hepatitis C virus core protein promotes proliferation of human hepatoma cells through enhancement of transforming growth factor alpha expression via activation of nuclear factor-kappaB.

Authors:  Y Sato; J Kato; R Takimoto; K Takada; Y Kawano; K Miyanishi; M Kobune; Y Sato; T Takayama; T Matunaga; Y Niitsu
Journal:  Gut       Date:  2006-03-31       Impact factor: 23.059

8.  Predictors of survival in patients with established cirrhosis and hepatocellular carcinoma treated with sorafenib.

Authors:  Andrea L Inghilesi; Donatella Gallori; Lorenzo Antonuzzo; Paolo Forte; Daniela Tomcikova; Umberto Arena; Stefano Colagrande; Silvia Pradella; Bernardo Fani; Elena Gianni; Luca Boni; Giacomo Laffi; Francesco Di Costanzo; Fabio Marra
Journal:  World J Gastroenterol       Date:  2014-01-21       Impact factor: 5.742

Review 9.  Hepatocellular carcinoma: Will novel targeted drugs really impact the next future?

Authors:  Liliana Montella; Giovannella Palmieri; Raffaele Addeo; Salvatore Del Prete
Journal:  World J Gastroenterol       Date:  2016-07-21       Impact factor: 5.742

10.  Sorafenib for the treatment of unresectable hepatocellular carcinoma.

Authors:  Junji Furuse
Journal:  Biologics       Date:  2008-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.